St. Jude Children’s Research Hospital, the American Society of Hematology (ASH), and Munich Leukemia Laboratory launched the ASH HematOmics Program (ASHOP), described as an integrative data platform for hematologic cancer research. The program is designed to unify genomics, transcriptomics, and clinical data from nearly 6,000 patients across diverse blood cancers. The platform’s stated goal is to support faster scientific discovery by standardizing and connecting multi-omic datasets to clinical outcomes—reducing the friction that typically slows hypothesis generation and validation in translational studies. For industry, the move reinforces how large-scale consortia and data infrastructure increasingly function as enabling platforms for pipeline work, biomarker development, and trial design within hematology.